DPP4 assay kit
- Known as:
- DPP4 test reagent
- Catalog number:
- 80204
- Product Quantity:
- 100 reactions
- Category:
- Peptides
- Supplier:
- BPS Bioscience
- Gene target:
- DPP4 assay kit
Related genes to: DPP4 assay kit
- Gene:
- DPP4 NIH gene
- Name:
- dipeptidyl peptidase 4
- Previous symbol:
- CD26, ADCP2
- Synonyms:
- DPPIV
- Chromosome:
- 2q24.2
- Locus Type:
- gene with protein product
- Date approved:
- 1990-03-05
- Date modifiied:
- 2016-02-05
Related products to: DPP4 assay kit
Human ELC ELISA KIT 96 TEST
OxiSelect Hydroxyl Radical Antioxidant Capacity (HORAC) Activity Assay, Trial Size
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: DPP4 assay kit
- Avian influenza viruses circulate naturally among migratory wild birds but can occasionally infect other species, including poultry and a broad range of mammals and humans. Although highly pathogenic avian influenza viruses (AIVs) are known to infect humans, low-pathogenic AIVs, particularly H7N9 and H9N2 subtypes, have also caused human infections and pose an ongoing zoonotic risk. In this study, we used single-cell transcriptomics to examine the cellular responses of human (A549) and chicken (DF-1) cells 24 h after infection with the zoonotic H9N2 virus. Our findings revealed distinct transcriptional responses between the two cell lines. Notably, dipeptidyl peptidase-4 (DPP4) and carboxypeptidase Q (CPQ) genes were expressed at significantly higher levels in infected DF-1 cells than in A549 cells, suggesting a potential role in viral replication. Overexpression of CPQ and DPP4 in A549 cells resulted in significantly greater viral replication compared to mock-transfected wild-type cells infected with the avian influenza H9N2 virus. Furthermore, Gene Set Enrichment Analysis of differentially expressed genes revealed downregulation of lipid metabolism pathways in cell clusters highly expressing H9N2 virus genes in both A549 and DF-1 cells, indicating a potential link between host lipid metabolism and H9N2 virus replication. These results provide insights into the transcriptional responses of A549 and DF-1 cells to H9N2 infection and identify candidate host factors and pathways associated with viral replication. These findings provide a foundation for future studies using physiologically relevant models to investigate the cellular determinants of H9N2 infection. - Source: PubMed
Publication date: 2026/09/03
Oldensand FannyRafati NimaVan Hoef VincentLundkvist ÅkeDarweesh MahmoudEllström PatrikNaguib Mahmoud M - Diabetes mellitus is a major global health concern. DPP-4 (dipeptidyl peptidase-4) inhibitors containing a 2-cyanopyrrolidine scaffold are in clinical use; however, systematic evaluation of amides derived from amino acids adjacent to the -2 position of GLP-1 (glucagon-like peptide-1) has not been reported. - Source: PubMed
Guo LiyuanDi ManDong ZhiyanZhang DaZhu XiaoqingWu ShiLiu Chao - SGLT-2 inhibitors are now used beyond type 2 diabetes (T2DM) in heart failure (HF) and chronic kidney disease (CKD), where glucose is monitored less routinely. Whether their established ketoacidosis signal-particularly euglycaemic diabetic ketoacidosis (euDKA)-is maintained as the indications expand, and whether it reproduces across independent reporting systems, is untested. We analysed the US FAERS (2020Q1-2026Q1) and Japanese JADER using one pipeline. Signals required consensus across four methods (ROR, PRR, IC, EBGM/EB05). Analyses were run overall, within report-level indication strata [T2DM, HF, CKD, off-label type 1 diabetes (T1DM)] and against an active comparator (DPP-4 inhibitors), with two pre-specified negative controls, time-to-onset modelling and sensitivity analyses. The DKA signal met four-method consensus within every indication stratum, including HF and CKD, and was highest in off-label T1DM; it was therefore maintained, not diluted, as indications expanded. Overall RORs were 67.4 (95% CI 65.7-69.2) in FAERS and 112.3 (104.8-120.3) in JADER. SGLT-2 inhibitors accounted for 85.8% (FAERS) and 91.7% (JADER) of all euDKA reports, though euDKA was only 4.1% and 7.8% of SGLT-2 inhibitor reports. Both negative controls were null in both databases. Median time-to-onset was 60 days (Weibull β=0.48, 95% CI 0.46-0.50). Across two independent reporting systems, the SGLT-2 inhibitor ketoacidosis signal was maintained across the expanding cardiorenal indications, with euDKA concentrated within this class and early onset. Ketone-based assessment is warranted when ketoacidosis is suspected, particularly soon after initiation. As a disproportionality analysis, these are hypothesis-generating signals that cannot establish incidence, relative risk, or causality. - Source: PubMed
Publication date: 2026/09/03
Chen JinqianWang DeyinDuan XiaochuanWang JianboZhao ZhenyuXing Xiaolong - Respiratory viral infections caused by seasonal influenza, respiratory syncytial virus (RSV), and pandemic-potential coronaviruses are responsible for several million hospitalisations and an estimated several hundred thousand deaths each year, a burden underscored by the severe 2024-2025 influenza season and the continued emergence of zoonotic threats such as clade 2.3.4.4b H5N1. This review critically examines the pharmacological basis for targeting host cell-surface receptors as a strategy for the treatment and prophylaxis of respiratory viral infections, evaluates the current evidence for each major receptor axis, and identifies the key translational gaps that must be addressed. Respiratory viruses, including influenza, RSV, SARS-CoV-2, and MERS-CoV, collectively cause millions of hospitalisations annually, and the persistent challenges of antigenic drift, zoonotic emergence, and antiviral resistance highlight the need for mechanistically distinct strategies. Host-directed therapies (HDTs) targeting conserved receptors (ACE2, DPP4, sialic acids, TMPRSS2) exploit genetically stable host factors required for viral entry. Across the receptor axes reviewed here, we appraise more than a dozen candidate agents spanning preclinical development through Phase III evaluation, including TMPRSS2 inhibitors, soluble ACE2 decoys, anti-CD147 and receptor-blocking monoclonal antibodies, the sialidase fusion protein DAS181, and avian IgY preparations. This evidence reveals a consistent gap between robust preclinical activity and as-yet-limited clinical efficacy. We conclude that host receptor targeting is a mechanistically rational but still clinically unproven component of the respiratory antiviral landscape; its value is most plausibly realised in defined niches-prophylaxis, early outpatient treatment, and combination with direct-acting antivirals-and within pandemic preparedness frameworks, provided that the safety, delivery, and trial-design challenges identified here are resolved. - Source: PubMed
Publication date: 2026/08/18
El-Kafrawy Sherif AOthman Norah AZeyadi MustafaEl-Daly Mai MAzhar Esam I - To examine the association between initiation of sodium-glucose cotransporter-2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase-4 (DPP-4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin. - Source: PubMed
Publication date: 2026/09/01
Park SangwooJeong SeogsongKim Hye JunLee Dae HoChoi Soo JungPark Sang Min